P2RX7 and cancer: Antagonists of P2X7 or P2Y12 receptors, therefore, not only reduce the levels of phosphorylated p38 and p42/44 MAPK, but also show reduction in COX-2 levels and abolish migration/invasive properties of the cancer cells in response to eATP.